{"id":"vigamox-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye irritation"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Taste perversion"}]},"_chembl":{"chemblId":"CHEMBL5940488","moleculeType":null,"molecularWeight":"498.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Moxifloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and repair. This dual inhibition prevents bacterial DNA from unwinding and replicating, leading to rapid bactericidal activity. The ophthalmic formulation delivers high local concentrations to the eye to treat bacterial infections of the ocular surface.","oneSentence":"Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:13.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial conjunctivitis"},{"name":"Bacterial keratitis"},{"name":"Bacterial corneal ulcer"}]},"trialDetails":[{"nctId":"NCT07225699","phase":"NA","title":"IN PATIENTS WITH CORNEAL ABRASIONS TREATED WITH COLLAGEN CORNEAL SHIELDS IN THE EMERGENCY DEPARTMENT SETTING","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-05-15","conditions":"Corneal Abrasions","enrollment":60},{"nctId":"NCT07394257","phase":"NA","title":"Intrastromal Moxifloxacin as an Adjunctive Therapy in Recalcitrant Bacterial Keratitis","status":"RECRUITING","sponsor":"Minia University","startDate":"2025-10-01","conditions":"Bacterial Keratitis, Recalcitrant Infectious Keratitis, Corneal Ulcer","enrollment":60},{"nctId":"NCT07305987","phase":"PHASE3","title":"PRO-232 in Patients Subjected to Cataract Surgery","status":"RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-10-27","conditions":"Cataract Extraction","enrollment":134},{"nctId":"NCT06271772","phase":"PHASE3","title":"Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction II","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-07-01","conditions":"Bacterial Keratitis","enrollment":60},{"nctId":"NCT06352541","phase":"PHASE1","title":"Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.","status":"NOT_YET_RECRUITING","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2025-09-30","conditions":"Healthy","enrollment":28},{"nctId":"NCT05331664","phase":"PHASE4","title":"Dropless Pars Plana Vitrectomy Study","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2022-07-25","conditions":"Rhegmatogenous Retinal Detachment","enrollment":168},{"nctId":"NCT06363292","phase":"PHASE1","title":"Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2024-01-30","conditions":"Ophthalmological Agent Toxicity, Bacterial Conjunctivitis","enrollment":37},{"nctId":"NCT06785090","phase":"PHASE4","title":"Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Inas Abd","startDate":"2023-05-01","conditions":"Cataract, Cystoid Macular Edema After Phacoemulsification","enrollment":87},{"nctId":"NCT04750655","phase":"PHASE4","title":"Antibiotic Resistance In Eye Surgeries","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-03-01","conditions":"Antibiotic Resistance, Ocular Surface Microbiome, Gut Resistome","enrollment":108},{"nctId":"NCT06163105","phase":"NA","title":"The Effect of Gland Expression on the Regeneration of Meibomian Gland","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2024-10-03","conditions":"Meibomian Gland Dysfunction","enrollment":64},{"nctId":"NCT06879301","phase":"EARLY_PHASE1","title":"Effectiveness of Intravitreal Injection of Aflibercept 8 mg in Resistant Diabetic Macular Edema, Retinal Vein Occlusion and Myopic Choroidal Neovascularisation Patients","status":"NOT_YET_RECRUITING","sponsor":"Tanta University","startDate":"2025-10-19","conditions":"Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO), Myopic Choroidal Neovascularisation","enrollment":60},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT06681688","phase":"PHASE1, PHASE2","title":"Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC","status":"RECRUITING","sponsor":"Inder Paul Singh, M.D.","startDate":"2024-07-10","conditions":"Cataract","enrollment":94},{"nctId":"NCT05413980","phase":"","title":"Effectiveness and Safety of 0.5% Moxifloxacin Hydrochloride Ophthalmic Solution in Perioperative Sterilization in Patients Undergoing Ophthalmic Surgery","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-01-27","conditions":"Post Operative Endophthalmitis","enrollment":102},{"nctId":"NCT05655689","phase":"","title":"The Antibiogram and Outcomes of Antimicrobial Regimens in Microbial Keratitis: A Prospective Cohort Study","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2021-12-31","conditions":"Bacterial Keratitis, Fungal Keratitis, Mixed Bacterial and Fungal Keratitis","enrollment":123},{"nctId":"NCT05741632","phase":"PHASE1","title":"Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2023-02-01","conditions":"Cataract","enrollment":68},{"nctId":"NCT04204122","phase":"PHASE2","title":"Vigamox Treatment for Ocular Graft-Versus-Host Disease","status":"WITHDRAWN","sponsor":"Washington University School of Medicine","startDate":"2020-06-15","conditions":"Ocular Graft-versus-host Disease","enrollment":""},{"nctId":"NCT04521140","phase":"PHASE4","title":"Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery","status":"COMPLETED","sponsor":"Nicole Fram M.D.","startDate":"2020-10-16","conditions":"Corneal Edema, Corneal Defect, Corneal Transplant","enrollment":36},{"nctId":"NCT03634852","phase":"PHASE4","title":"A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery","status":"COMPLETED","sponsor":"Suzan A Rattan","startDate":"2016-10-01","conditions":"Endophthalmitis Postoperative","enrollment":1000},{"nctId":"NCT05665270","phase":"PHASE4","title":"A Study for Post op Inflammation After Cataract Surgery","status":"UNKNOWN","sponsor":"Wyse Eyecare","startDate":"2023-01-30","conditions":"Cataract","enrollment":40},{"nctId":"NCT05255107","phase":"PHASE2, PHASE3","title":"Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers","status":"UNKNOWN","sponsor":"Peschke GmbH","startDate":"2022-03-14","conditions":"Keratitis, Corneal Ulcer","enrollment":468},{"nctId":"NCT05428683","phase":"NA","title":"Intravitreal Triamcinolone and Moxifloxacin Injection After Cataract Surgery","status":"COMPLETED","sponsor":"Emad Abdel Aal Saliem","startDate":"2020-12-03","conditions":"Pharmacological Action","enrollment":84},{"nctId":"NCT05331859","phase":"PHASE1","title":"Topical Insulin Versus Autologous Serum After Corneal Surgeries","status":"UNKNOWN","sponsor":"Benha University","startDate":"2022-05","conditions":"Corneal Epithelial Wound","enrollment":250},{"nctId":"NCT03580473","phase":"PHASE2","title":"Efficacy and Safety of Saturno IIB Association on the Control of Ocular Inflammation Post-phacoemulsification","status":"COMPLETED","sponsor":"EMS","startDate":"2020-02-27","conditions":"Ocular Inflammation, Cataract","enrollment":118},{"nctId":"NCT05162625","phase":"PHASE2","title":"Safety and Efficacy of Topical Moxifloxacin for Prevention of Post-Traumatic Endophthalmitis: Randomized Controlled Clinical Trial","status":"UNKNOWN","sponsor":"University of Campinas, Brazil","startDate":"2021-12-10","conditions":"Endophthalmitis, Open Globe Injury, Moxifloxacin","enrollment":100},{"nctId":"NCT03640650","phase":"PHASE4","title":"Economic Impact of Dropless Therapy Versus Usual Care for Cataract Surgery: A Real-World Study.","status":"TERMINATED","sponsor":"PeriPharm","startDate":"2018-08-15","conditions":"Cataract Surgery","enrollment":80},{"nctId":"NCT01296191","phase":"PHASE4","title":"Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification","status":"COMPLETED","sponsor":"Frank A. Bucci, Jr., M.D.","startDate":"2011-05","conditions":"Cataracts","enrollment":120},{"nctId":"NCT04273282","phase":"PHASE4","title":"A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%","status":"COMPLETED","sponsor":"Research Insight LLC","startDate":"2019-12-16","conditions":"Cataract","enrollment":31},{"nctId":"NCT01296542","phase":"PHASE4","title":"A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery","status":"COMPLETED","sponsor":"Bucci Laser Vision Institute","startDate":"2011-05","conditions":"Cataracts","enrollment":60},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT04212429","phase":"PHASE1, PHASE2","title":"The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis Postoperative","enrollment":128},{"nctId":"NCT04214821","phase":"PHASE1, PHASE2","title":"The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%","status":"UNKNOWN","sponsor":"National University of Malaysia","startDate":"2019-09-23","conditions":"Endophthalmitis","enrollment":128},{"nctId":"NCT04205916","phase":"PHASE4","title":"A Trial Evaluating Patient Preference of Dropless vs Drops Post Cataract Surgery","status":"RECRUITING","sponsor":"Ophthalmic Consultants of Long Island","startDate":"2019-11-04","conditions":"Patient Preference","enrollment":50},{"nctId":"NCT00690313","phase":"PHASE4","title":"Dosage Study for Vigamox Eye Drops Prior to Intravitreal Injections","status":"COMPLETED","sponsor":"Illinois Retina Associates","startDate":"2008-08","conditions":"Intravitreal Injection Patients","enrollment":22},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":"Bacterial Conjunctivitis","enrollment":150},{"nctId":"NCT02515045","phase":"PHASE4","title":"Dropless vs. Standard Drops Contralateral Eye Study","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2015-01","conditions":"Cataract","enrollment":59},{"nctId":"NCT00759148","phase":"PHASE3","title":"Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Bacterial Conjunctivitis","enrollment":1179},{"nctId":"NCT00924729","phase":"PHASE4","title":"Study of Ocular Penetration of Topically Administered Fluoroquinolones","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-09","conditions":"Cataract Extraction","enrollment":50},{"nctId":"NCT00332293","phase":"PHASE3","title":"AL-15469A for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-05","conditions":"Bacterial Conjunctivitis","enrollment":695},{"nctId":"NCT02865876","phase":"PHASE3","title":"Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis","status":"UNKNOWN","sponsor":"Instituto de Oftalmología Fundación Conde de Valenciana","startDate":"2015-06","conditions":"Keratitis","enrollment":264},{"nctId":"NCT00581542","phase":"PHASE4","title":"Moxifloxacin vs. Polytrim for Conjunctivitis","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2007-03","conditions":"Conjunctivitis","enrollment":124},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":"Corneal Ulcers","enrollment":2},{"nctId":"NCT01573910","phase":"PHASE3","title":"An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-05","conditions":"Bacterial Conjunctivitis","enrollment":985},{"nctId":"NCT00348348","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2006-06","conditions":"Acute Bacterial Conjunctivitis","enrollment":1161},{"nctId":"NCT01515826","phase":"PHASE3","title":"VIGADEXA Gel Compared to VIGADEXA Solution Following Cataract Surgery","status":"WITHDRAWN","sponsor":"Alcon Research","startDate":"2014-03","conditions":"Cataracts","enrollment":""},{"nctId":"NCT01859702","phase":"PHASE4","title":"Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-04","conditions":"Cataract","enrollment":36},{"nctId":"NCT00414011","phase":"NA","title":"Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"","conditions":"Epithelium, Corneal","enrollment":40},{"nctId":"NCT00579020","phase":"PHASE2","title":"A Phase II Study of Moxidex Ophthalmic Solution for Treatment of Marginal Corneal Infiltrates","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2007-12","conditions":"Corneal Infiltrates","enrollment":144},{"nctId":"NCT00312338","phase":"PHASE4","title":"Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-06","conditions":"Bacterial Conjunctivitis","enrollment":137},{"nctId":"NCT00840580","phase":"PHASE4","title":"Effect on Wound Healing of Vigamox Versus Cravit","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-01","conditions":"Cataract Extraction","enrollment":79},{"nctId":"NCT01577342","phase":"NA","title":"Determining the Effect of Antibiotic Drop Prophylaxis on the Conjunctival Flora","status":"COMPLETED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2010-11","conditions":"Age-Related Macular Degeneration","enrollment":56},{"nctId":"NCT00758199","phase":"PHASE4","title":"Determination of Optimum Duration of Treatment With Bromfenac (Xibrom) Eyedrops Following Cataract Surgery","status":"COMPLETED","sponsor":"Bp Consulting, Inc","startDate":"2008-07","conditions":"Cataracts","enrollment":49},{"nctId":"NCT00666042","phase":"NA","title":"Bioequivalence of Eye Drops and Spray Administration of Vigamox","status":"COMPLETED","sponsor":"Advanced Ophthalmic Pharma","startDate":"2009-02","conditions":"Cataract","enrollment":16},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT00905762","phase":"PHASE1","title":"Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-03","conditions":"Healthy","enrollment":119},{"nctId":"NCT01455233","phase":"PHASE4","title":"2-Site Safety Study of Besivance Versus Vigamox Prophylactically in Routine Cataract Surgery","status":"COMPLETED","sponsor":"Ophthalmology Consultants, Ltd.","startDate":"2010-09","conditions":"Corneal Health, Cataract Surgery","enrollment":60},{"nctId":"NCT00564447","phase":"PHASE4","title":"Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections","enrollment":48},{"nctId":"NCT00575380","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox Concentrations in the Conjunctiva and Aqueous Humor in Subjects Undergoing Routine Cataract Surgery","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-12","conditions":"Bacterial Infections, Eye Infections, Cataract Extraction","enrollment":116},{"nctId":"NCT00575367","phase":"PHASE4","title":"Study of AzaSite Versus Vigamox in the Tears of Healthy Volunteers","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-03","conditions":"Bacterial Infections, Eye Infections","enrollment":37},{"nctId":"NCT00464438","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-06","conditions":"Bacterial Conjunctivitis","enrollment":171},{"nctId":"NCT00732446","phase":"PHASE3","title":"Safety/Efficacy of Antibiotic Steroid Combination in Treatment of Blepharitis and/or Keratitis and/or Conjunctivitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2008-08","conditions":"Blepharitis, Conjunctivitis, Keratitis","enrollment":100},{"nctId":"NCT00798577","phase":"PHASE4","title":"Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Bacterial Conjunctivitis","enrollment":24},{"nctId":"NCT00870103","phase":"PHASE4","title":"Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-09","conditions":"Cataract","enrollment":64},{"nctId":"NCT00764582","phase":"PHASE4","title":"Ocular Penetration of 1.5% Levofloxacin and 0.5% Moxifloxacin During Corneal Transplant Surgery","status":"TERMINATED","sponsor":"Santen Inc.","startDate":"2008-09","conditions":"Corneal Transplantation","enrollment":60},{"nctId":"NCT00892918","phase":"NA","title":"Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2009-06","conditions":"Primary Pterygium","enrollment":40},{"nctId":"NCT00565630","phase":"NA","title":"Using Device Delivering Ophthalmic Solution in a Spray Form Instead of Eye Drops","status":"WITHDRAWN","sponsor":"Advanced Ophthalmic Pharma","startDate":"2008-01","conditions":"Cataract","enrollment":16},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00630019","phase":"PHASE4","title":"Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-02","conditions":"Cataract","enrollment":96},{"nctId":"NCT00347828","phase":"PHASE4","title":"Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2006-06","conditions":"Eye Infection, Infection","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":123,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vigamox(moxifloxacin hydrochloride ophthalmic solution)"],"phase":"marketed","status":"active","brandName":"Vigamox Eye Drops","genericName":"Vigamox Eye Drops","companyName":"Merck Sharp & Dohme LLC","companyId":"merck","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vigamox Eye Drops are used to treat various eye conditions, including Acute Bacterial Conjunctivitis, Bacterial Infections, and Eye Infections, as well as Cataract and Meibomian Gland Dysfunction. The active ingredient in Vigamox Eye Drops is Moxifloxacin HCl 0.5%, which is delivered in a solution form.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}